Data confusion

Kidney International

Volumn 88, Issue 6, 2015, Pages 1445-

  Bhandari, Sunil ^a   Kalra, Philip A ^b   Coyne, Daniel W ^c  

^a HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON COMPLEX; PLACEBO;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; HEART FAILURE; HUMAN; LETTER; PRIORITY JOURNAL; WALKING SPEED;

EID: 84949818798     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.303     Document Type: Letter

References (4)

1. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-914
2. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084
3. Kalra PA, Bhandari S, Saxena S et al. A randomised trial of iron isomaltoside 1000 versus oral iron in non-dialysis dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2015 (e-pub ahead of print; doi:10.1093/ndt/gfv293)
4. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657-668 (published online ahead of print 31 August 2014).